This company develops a minimally invasive surgical device that uses photodynamic therapy to treat aggressive brain tumors. Their device delivers light to cancer cells exposed to a photosensitizer, offering patients a less invasive alternative to traditional brain surgery.

Auron utilizes a proprietary database of single-cell genomic data and an AI-powered computational platform to map the developmental pathways of cancer cells compared to healthy cells. This approach aims to transform malignant cells into normal functioning cells, addressing the limitations of traditional cancer therapeutics that primarily focus on cell killing.

Clasp Therapeutics develops precision immunotherapies using proprietary pHLAre™ T cell engagers that target mutated protein fragments on cancer cells, enabling the immune system to selectively destroy tumors with specific driver mutations. This approach addresses the limitations of current immuno-oncology treatments by expanding therapeutic options for patients with hard-to-treat cancers.

Freenome provides a blood‑based early cancer detection platform that uses multiomics profiling—integrating genomics, epigenomics, proteomics, and metabolomics—with AI‑driven analysis to identify cancer at its most treatable stages. The minimally invasive test is designed for routine screening across multiple cancer types and is validated through ongoing clinical programs for use by healthcare providers.

Immunitas Therapeutics utilizes single-cell genomics to develop targeted antibody-based therapies for cancer and autoimmune diseases, focusing on the CD161-CLEC2D pathway. Their lead candidate, IMT-009, is currently in clinical trials for treating refractory tumors, addressing the need for effective treatments in patients with limited options.

Interius BioTherapeutics develops in vivo lentivector gene therapies specifically targeting B cell lymphomas, utilizing programmable vectors for precise genetic medicine delivery. The company aims to provide effective treatment options for patients with challenging hematological malignancies, addressing the need for targeted therapies in oncology.

Mercy BioAnalytics utilizes its proprietary Mercy Halo™ platform, which employs low-cost qPCR technology to detect cancer-associated biomarkers on extracellular vesicles in blood samples. This approach addresses the challenge of late cancer diagnoses by providing highly sensitive and specific tests for early-stage cancer detection, improving treatment options and patient outcomes.

Naveris develops liquid biopsies that utilize proprietary technology to detect HPV-related cancers through highly sensitive blood tests, enabling earlier diagnosis than traditional imaging or biopsies. Their lead product, NavDx®, provides real-time monitoring of cancer recurrence, improving patient outcomes by facilitating timely interventions.

Nusano utilizes a proprietary ion source and particle acceleration technology to produce over 40 types of radioisotopes efficiently and affordably, addressing the critical shortage in supply for medical, industrial, and clean energy applications. Their radioisotopes enable precise cancer treatments, enhance industrial operations, and facilitate the generation of clean energy from nuclear waste.

Paradigm is developing a platform that integrates clinical trial management systems to enhance trial efficiency and reduce participation barriers for both patients and healthcare providers. By creating a unified infrastructure, Paradigm aims to provide equitable access to clinical trials, accelerating the delivery of potentially life-saving therapies.

Persephone Biosciences utilizes artificial intelligence and synthetic biology to develop microbial-based immunotherapies that restore human microbiomes, addressing the health impacts of damaged ecosystems. Their approach aims to enhance therapeutic responses and improve patient outcomes in the fight against cancer.

Sonata Therapeutics is developing Network Medicines™ that reprogram diseased cells to release therapeutic signals, coordinating multicellular networks to drive disease resolution in cancer, fibrosis, and autoimmune disorders. This approach addresses the challenge of dysfunctional cell signaling in disease progression by enabling a targeted, holistic treatment strategy that enhances the efficacy of therapeutic interventions.

Provides a financial navigation platform that integrates with EMR, pharmacy, and practice management systems to identify and match patients with over 6,000 financial assistance resources, including copay cards and government programs. By streamlining enrollment processes and projecting out-of-pocket costs, it reduces financial barriers to treatment, improving access and affordability for patients across all conditions.